LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company’s LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
Their Purpose is to be a driving force in the early detection to lung cancer. And their Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.
Inaugural Annual Report
Having raised gross proceeds of £17 million when they floated on AIM in July 2021, the Company needed to produce their inaugural Annual Report as a further stage of their corporate journey as a listed company. The Perivan Shareholder Communications team were delighted to be appointed to design and produce the publication which has successfully been published and posted to shareholders.
Commenting on his experience in working with our team, David Anderson, Chief Financial Officer at LungLife said:
“Received the accounts today and thanks for the care and attention over the last few weeks. You’ve smashed the art of client care – making the smallest account feel like they’re the biggest”.
To view the full annual report, click here:
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.